TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Department of Health and Human Services has submitted an interim peptide access policy to the White House Office of Management and Budget for review. People familiar with the proposal say it would let specialty pharmacies temporarily compound some popular peptides, including BPC-157, but the filing does not specify which substances or when the policy might take effect.
The Department of Health and Human Services has sent an interim policy on peptide access to the White House Office of Management and Budget for review, advancing a plan that could let specialty pharmacies temporarily compound some of the products. Two people familiar with the proposal told MedPage Today it could cover popular peptides such as BPC-157; the government filing itself does not identify the substances or set out the policy’s terms.
The filing, listed on a government website Thursday, is titled an “interim access policy.” The Office of Management and Budget reviews federal rules and policies that may have significant economic effects. HHS officials did not immediately respond to MedPage Today’s request for comment, and the submission does not explain how the policy would work or when it might take effect.
According to the two people familiar with the plan, the proposal would use enforcement discretion: the Food and Drug Administration would choose not to enforce certain restrictions against pharmacies compounding some peptides, at least temporarily. That differs from formally adding substances to the FDA’s list of drugs considered safe for compounding, which would require federal rulemaking and public comment. It is not clear whether the administration also plans to pursue that formal process.
The products under discussion are distinct from approved peptide-based medicines, including some used to treat diabetes or obesity. Many wellness-promoted injectable peptides have not undergone the same testing and review as approved drugs. Their use for goals such as muscle building, injury recovery, or energy is not FDA-approved, and much of the evidence cited for them comes from animal studies, MedPage Today reported.
Potential Effects on Pharmacy Access
If adopted, the policy could make some peptides more accessible through U.S. specialty pharmacies rather than leaving consumers to seek products through online or other unregulated channels. HHS Secretary Robert F. Kennedy Jr. has argued that Americans are turning to “gray market” peptides from China and elsewhere, and has said domestic compounding pharmacies should be allowed to sell them. Those statements describe the administration’s rationale, not evidence that compounded products are safe or effective.
The decision could also affect a growing commercial market. MedPage Today reported that major telehealth providers Hims & Hers and Noom have announced plans to offer peptides if federal policy permits, while Wall Street analysts estimate the market could reach $2 billion to $3 billion. Those are market estimates, not a confirmed measure of current sales. A change in enforcement policy could alter access without giving the products FDA approval or establishing their safety and effectiveness.
Products Worth Considering
Therabody JetBoots Prime Wireless Compression Boots (Short, Under 29-Inch Inseam)
Blueair Blue Pure 511i Max Smart Air Purifier
Oura Ring 5 Smart Ring, Gold, Size 8
As an affiliate, we earn on qualifying purchases.
How the FDA Review Reached This Point
The FDA previously placed BPC-157 and more than a dozen injectable peptides on a list of substances considered too risky for compounding. The agency has cited potential concerns including contamination, allergic reactions, and tumor growth. These are identified risks; the supplied report does not establish that every product or use causes those harms.
Kennedy called for reconsideration of a short list of peptides after taking office as health secretary. In July, an external FDA advisory panel recommended removing restrictions on six of the seven peptides it reviewed. The panel was selected by Kennedy’s department and included people working as doctors, pharmacists, and consultants in the peptide field. FDA staff scientists had maintained that the substances had not been studied enough to establish safety and effectiveness. The advisers’ recommendation was not itself an FDA approval or a change in the rules.
““FDA’s war” on peptides and other wellness products would soon end.”
— Robert F. Kennedy Jr., before joining the administration, as quoted by MedPage Today
Policy Scope and Safety Questions
The White House filing provides no public list of peptides covered, and the people who described the plan spoke anonymously about confidential deliberations. The proposal’s duration, conditions for pharmacy compounding, and route to implementation are also unknown. It has been submitted for review, not announced as a final policy.
It is also unclear whether the administration will seek formal rule changes alongside enforcement discretion. That distinction matters: a decision not to pursue certain enforcement actions would not, on its own, place peptides on an FDA list of substances safe for compounding or establish that they are effective for wellness uses. The FDA’s stated concerns and the limited research remain relevant as officials weigh any change.
White House Review and Agency Decisions
The immediate next step is review by the Office of Management and Budget. The source report gives no date for a decision, publication, or start of any temporary policy. HHS and the FDA have not publicly set out the proposal’s terms in the material cited.
Readers should look for an official policy text or statement identifying which peptides might be covered, how long the approach would last, and what standards pharmacies would have to meet. Any separate formal rulemaking would involve additional review and public comment, and could take years. Until the administration publishes further details, the reported plan should be treated as a proposal under review, not as a new authorization for peptide products.
Key Questions
What has the Trump administration done so far?
HHS submitted an interim peptide access policy to the White House Office of Management and Budget for review. The submission is a step in the process, not confirmation that the policy is final or in effect.
Which peptides could be affected?
The filing does not name any. Two people familiar with the proposal told MedPage Today it could include BPC-157 and other popular peptides, but the full list has not been publicly confirmed.
Would the plan make peptides FDA-approved?
No approval is described in the report. The plan is reportedly based on enforcement discretion, a decision about whether to enforce certain restrictions. That is different from FDA approval or a formal finding that a substance is safe and effective.
What safety concerns has the FDA raised?
The FDA previously cited possible contamination, allergic reactions, and tumor growth among concerns about certain injectable peptides compounded by pharmacies. The report also says evidence for many wellness uses is limited and often comes from animal studies.
When could pharmacies begin compounding the peptides?
No start date has been announced. The proposal is under White House review, and the public filing does not provide a timeline or explain the conditions pharmacies would need to follow.
Source: rss
